SML0492

Zanamivir

Name: Zanamivir
Brand: SIGMA

≥98% (HPLC), Influenza viral neuraminidase inhibitor, powder

Sinónimos:

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid, 4-Guanidino-Neu5Ac2en

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₁₂H₂₀N₄O₇

Número CAS:

139110-80-8

Peso molecular:

332.31

UNSPSC Code:

12352200

PubChem Substance ID:

329825442

NACRES:

NA.77

MDL number:

MFCD00866966

Nombre del producto

Zanamivir, ≥98% (HPLC)

SMILES string

CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O

InChI

1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

InChI key

ARAIBEBZBOPLMB-UFGQHTETSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +30 to +40°, c = 1 in H₂O

color

white to beige

solubility

H₂O: 10 mg/mL, clear

storage temp.

room temp

Quality Level

100

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Application

Zanamivir has been used:

as a neuraminidase inhibitor to study its effects on influenza A virus (IAV) like particles
as a neuraminidase inhibitor to study its effects on lipopolysaccharide (LPS)-mediated pathology in sepsis
as an antiviral to study its effects on influenza B virus by plaque reduction assay

Biochem/physiol Actions

Zanamivir exhibits therapeutic effects against influenza caused by influenza virus A and B.

Zanamivir is an influenza viral neuraminidase inhibitor.

pictograms

GHS07

signalword

Warning

hcodes

H302,H315,H319,H335

pcodes

P261 - P264 - P270 - P301 + P312 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.

Benjamin O Fulton et al.

Journal of virology, 89(23), 12226-12231 (2015-09-25)

Influenza B virus is a human pathogen responsible for significant health and economic burden. Research into this pathogen has been limited by the lack of reporter viruses. Here we describe the development of both a replication-competent fluorescent influenza B reporter

Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.

Javier Magano

Chemical reviews, 109(9), 4398-4438 (2009-06-23)

Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Carl J Heneghan et al.

BMJ (Clinical research ed.), 348, g2547-g2547 (2014-05-09)

To describe the potential benefits and harms of zanamivir. Systematic review of clinical study reports of randomised placebo controlled trials and regulatory information Clinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers. Randomised placebo controlled trials

Inhibiting influenza virus transmission using a broadly acting neuraminidase that targets host sialic acids in the upper respiratory tract.

Mila B Ortigoza et al.

mBio, 15(2), e0220323-e0220323 (2024-01-11)

The ongoing transmission of influenza A viruses (IAV) for the past century continues to be a burden to humans. IAV binds terminal sialic acids (SA) of sugar molecules present within the upper respiratory tract (URT) in order to successfully infect

Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.

Emi Takashita et al.

Antimicrobial agents and chemotherapy, 59(5), 2607-2617 (2015-02-19)

Between September 2013 and July 2014, 2,482 influenza 2009 pandemic A(H1N1) [A(H1N1)pdm09] viruses were screened in Japan for the H275Y substitution in their neuraminidase (NA) protein, which confers cross-resistance to oseltamivir and peramivir. We found that a large cluster of

Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico